Hanz—LNP Service Platform
Hanz Biotech has developed four technical service platforms based on its proprietary LNP technology: the extrahepatic delivery platform, gene editing platform, antibody conjugation platform, and iSCAR-T platform. These platforms offer multidimensional delivery capabilities across RNA, protein, and cell levels, providing efficient and practical solutions for a wide range of applications.
From basic research and drug screening to advanced therapy development, the Hanz-LNP platform offers customized support tailored to each project, accelerating translational outcomes and real-world implementation.
Extrahepatic Delivery Platform
Traditional LNPs mainly target the liver, limiting their use for non-hepatic diseases. Hanz Bio’s proprietary platform enables efficient delivery to the spleen, lungs, skin, and immune cells. Proven effective with mRNA, siRNA, circRNA, and gene editing tools, it offers a powerful solution for extrahepatic research and therapy development.
Gene Editing Platform
Hanz Bio’s LNP platform is optimized for delivering gene editing tools like CRISPR/Cas9, Cas12, and base editors. Supporting formats such as mRNA + sgRNA and RNPs, it enables efficient in vitro and in vivo editing for cell engineering, animal models, and therapeutic development.
Antibody Conjugation Platform
This platform combines the targeting capabilities of antibodies with LNPs using a chemical conjugation strategy to enable efficient coupling. The resulting antibody-LNP complexes allow for precise delivery to tumor cells and specific immune cell types, enhancing therapeutic selectivity and safety.
isCAR-T Platform
The isCAR-T platform delivers CAR mRNA directly to T cells in vivo using LNPs, enabling on-site T cell engineering without ex vivo steps. This approach simplifies treatment, lowers costs, and expands the potential of CAR-T therapies.